BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 23897252)

  • 1. BRAF V600E mutation analysis simplifies the testing algorithm for Lynch syndrome.
    Jin M; Hampel H; Zhou X; Schunemann L; Yearsley M; Frankel WL
    Am J Clin Pathol; 2013 Aug; 140(2):177-83. PubMed ID: 23897252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer.
    Capper D; Voigt A; Bozukova G; Ahadova A; Kickingereder P; von Deimling A; von Knebel Doeberitz M; Kloor M
    Int J Cancer; 2013 Oct; 133(7):1624-30. PubMed ID: 23553055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A modified Lynch syndrome screening algorithm in colon cancer: BRAF immunohistochemistry is efficacious and cost beneficial.
    Roth RM; Hampel H; Arnold CA; Yearsley MM; Marsh WL; Frankel WL
    Am J Clin Pathol; 2015 Mar; 143(3):336-43. PubMed ID: 25696791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency and application of the hot spot BRAF gene mutation (p.V600E) in the diagnostic strategy for Hereditary Nonpolyposis Colorectal Cancer.
    Kadiyska TK; Konstantinova DV; Atanasov VR; Kremensky IM; Mitev VI
    Cancer Detect Prev; 2007; 31(3):254-6. PubMed ID: 17566669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective, multicenter, population-based study of BRAF mutational analysis for Lynch syndrome screening.
    Bessa X; Ballesté B; Andreu M; Castells A; Bellosillo B; Balaguer F; Castellví-Bel S; Paya A; Jover R; Alenda C; Titó L; Martinez-Villacampa M; Vilella A; Xicola RM; Pons E; Llor X;
    Clin Gastroenterol Hepatol; 2008 Feb; 6(2):206-14. PubMed ID: 18096441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for Lynch syndrome and referral to clinical genetics by selective mismatch repair protein immunohistochemistry testing: an audit and cost analysis.
    Colling R; Church DN; Carmichael J; Murphy L; East J; Risby P; Kerr R; Chetty R; Wang LM
    J Clin Pathol; 2015 Dec; 68(12):1036-9. PubMed ID: 26201544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer.
    Hampel H; Pearlman R; Beightol M; Zhao W; Jones D; Frankel WL; Goodfellow PJ; Yilmaz A; Miller K; Bacher J; Jacobson A; Paskett E; Shields PG; Goldberg RM; de la Chapelle A; Shirts BH; Pritchard CC;
    JAMA Oncol; 2018 Jun; 4(6):806-813. PubMed ID: 29596542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing.
    Domingo E; Laiho P; Ollikainen M; Pinto M; Wang L; French AJ; Westra J; Frebourg T; Espín E; Armengol M; Hamelin R; Yamamoto H; Hofstra RM; Seruca R; Lindblom A; Peltomäki P; Thibodeau SN; Aaltonen LA; Schwartz S
    J Med Genet; 2004 Sep; 41(9):664-8. PubMed ID: 15342696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient molecular screening of Lynch syndrome by specific 3' promoter methylation of the MLH1 or BRAF mutation in colorectal cancer with high-frequency microsatellite instability.
    Nakagawa H; Nagasaka T; Cullings HM; Notohara K; Hoshijima N; Young J; Lynch HT; Tanaka N; Matsubara N
    Oncol Rep; 2009 Jun; 21(6):1577-83. PubMed ID: 19424639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness Analysis of Different Genetic Testing Strategies for Lynch Syndrome in Taiwan.
    Chen YE; Kao SS; Chung RH
    PLoS One; 2016; 11(8):e0160599. PubMed ID: 27482709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome.
    Toon CW; Walsh MD; Chou A; Capper D; Clarkson A; Sioson L; Clarke S; Mead S; Walters RJ; Clendenning M; Rosty C; Young JP; Win AK; Hopper JL; Crook A; von Deimling A; Jenkins MA; Buchanan DD; Gill AJ
    Am J Surg Pathol; 2013 Oct; 37(10):1592-602. PubMed ID: 23797718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular biology from bench-to-bedside - which colorectal cancer patients should be referred for genetic counselling and risk assessment.
    Jensen LH; Dysager L; Lindebjerg J; Kølvrå S; Byriel L; Crüger DG
    Eur J Cancer; 2010 Jul; 46(10):1823-8. PubMed ID: 20417091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population-based molecular screening for Lynch syndrome: implications for personalized medicine.
    Ward RL; Hicks S; Hawkins NJ
    J Clin Oncol; 2013 Jul; 31(20):2554-62. PubMed ID: 23733757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MLH1 promoter hypermethylation in the analytical algorithm of Lynch syndrome: a cost-effectiveness study.
    Gausachs M; Mur P; Corral J; Pineda M; González S; Benito L; Menéndez M; Espinàs JA; Brunet J; Iniesta MD; Gruber SB; Lázaro C; Blanco I; Capellá G
    Eur J Hum Genet; 2012 Jul; 20(7):762-8. PubMed ID: 22274583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical staining for p16 and BRAFV600E is useful to distinguish between sporadic and hereditary (Lynch syndrome-related) microsatellite instable colorectal carcinomas.
    Boissière-Michot F; Frugier H; Ho-Pun-Cheung A; Lopez-Crapez E; Duffour J; Bibeau F
    Virchows Arch; 2016 Aug; 469(2):135-44. PubMed ID: 27220764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is tumor testing efficiency for Lynch syndrome different in rectal and colon cancer?
    Marabelli M; Gandini S; Rafaniello PR; Calvello M; Tolva G; Feroce I; Lazzeroni M; Marino E; Dal Molin M; Trovato C; Guerrieri-Gonzaga A; Petz WL; Barberis M; Bertario L; Bonanni B
    Dig Liver Dis; 2020 Dec; 52(12):1503-1511. PubMed ID: 32620519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF mutation in sporadic colorectal cancer and Lynch syndrome.
    Thiel A; Heinonen M; Kantonen J; Gylling A; Lahtinen L; Korhonen M; Kytölä S; Mecklin JP; Orpana A; Peltomäki P; Ristimäki A
    Virchows Arch; 2013 Nov; 463(5):613-21. PubMed ID: 23963522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical detection of BRAF V600E mutant protein using the VE1 antibody in colorectal carcinoma is highly concordant with molecular testing but requires rigorous antibody optimization.
    Kuan SF; Navina S; Cressman KL; Pai RK
    Hum Pathol; 2014 Mar; 45(3):464-72. PubMed ID: 24529329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Screening for Lynch syndrome in colorectal cancer].
    Liu X; Cao Y; Wang C; Cao R; Chen X; Ding J; Geng M
    Zhonghua Bing Li Xue Za Zhi; 2014 Jun; 43(6):394-8. PubMed ID: 25208990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF
    Grillo F; Paudice M; Pigozzi S; Dono M; Lastraioli S; Lugaresi M; Bozzano S; Tognoni C; Ali M; Sciallero S; Puccini A; Fassan M; Mastracci L
    Histopathology; 2024 Apr; 84(5):877-887. PubMed ID: 38173291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.